GO:0032705 negative regulation of interleukin-21 production: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032705 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-21 (IL-21) production.
• IL-21 is a pleiotropic common gamma-chain cytokine that shapes T follicular helper (Tfh) cell, B cell, and myeloid responses, so its negative regulation is central to immune homeostasis.
• NR2F6 is a nuclear receptor that suppresses Tfh cell accumulation by directly constraining IL-21 production, providing a defined molecular entry point into GO:0032705.
• IL-21 acts as a broad negative regulator of IgE class switch recombination in both mouse and human B cells, illustrating why tuning IL-21 levels matters for allergic and autoimmune biology.
• Dysregulated IL-21 production is linked to systemic lupus erythematosus, chronic inflammatory diseases, and chronic HBV infection, making this GO term clinically relevant.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of candidate negative regulators of IL-21 production in primary and immortalized immune cells.
Description
GO:0032705, negative regulation of interleukin-21 production, is a biological process term in the Gene Ontology that captures any mechanism that stops, prevents, or reduces the frequency, rate, or extent of interleukin-21 (IL-21) production. IL-21 is a common gamma-chain cytokine produced predominantly by activated CD4+ T cells, including T follicular helper (Tfh) cells, and it signals through the IL-21 receptor to influence B cell differentiation, antibody class switching, and effector T cell programs. Because IL-21 sits at the intersection of humoral immunity, autoimmunity, and chronic inflammation, the processes that restrain its production are as important as the processes that induce it. Researchers annotate GO:0032705 when they can show experimentally that a perturbation reduces IL-21 protein or mRNA output, whether through transcriptional repression, altered T cell differentiation, or post-transcriptional control. The term is therefore used in immunology, autoimmunity, and infection biology to describe negative feedback and checkpoint mechanisms that keep IL-21 within a physiological range. Understanding these mechanisms helps explain why unchecked IL-21 production contributes to pathogenic effector B cell states in systemic lupus erythematosus and to chronic inflammatory disease pathology. This article summarizes the QuickGO definition, the major genes and pathways associated with negative regulation of IL-21 production, disease connections, and the CRISPR-based experimental models that can be used to study this process rigorously.
negative regulation of interleukin-21 production At A Glance
| GO ID | GO:0032705 |
|---|---|
| GO term | negative regulation of interleukin-21 production |
| Ontology | biological_process |
| Synonym | down regulation of interleukin-21 production; down-regulation of interleukin-21 production; downregulation of interleukin-21 production; negative regulation of interleukin-21 biosynthetic process |
| Major function | Reduces the frequency, rate, or extent of interleukin-21 production, thereby limiting IL-21-dependent immune activation |
| Cytokine family | IL-21 belongs to the common gamma-chain (gamma-c) cytokine family |
| Primary producer cells | Activated CD4+ T cells, including T follicular helper cells, and other immune cells |
| Representative negative regulator | NR2F6 suppresses Tfh cell accumulation through regulation of IL-21 |
| Disease relevance | Systemic lupus erythematosus, chronic inflammatory diseases, chronic HBV infection, IgE-mediated allergy |
What Is GO:0032705?
In plain terms, GO:0032705 refers to any cellular or molecular process that lowers the amount of interleukin-21 that a cell produces. The QuickGO definition states: Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-21 production. It is a biological_process term, and its synonyms include down regulation of interleukin-21 production, down-regulation of interleukin-21 production, downregulation of interleukin-21 production, and negative regulation of interleukin-21 biosynthetic process. The term does not specify a single molecular mechanism; instead, it groups transcriptional, post-transcriptional, and differentiation-level mechanisms that converge on reduced IL-21 output.
Why Is negative regulation of interleukin-21 production Important in Cell Biology?
Negative regulation of interleukin-21 production is important because IL-21 is a potent amplifier of humoral and cellular immunity, and its excessive or prolonged production is associated with pathogenic effector B cell expansion in systemic lupus erythematosus, chronic inflammatory disease, and other immune-mediated conditions. Conversely, IL-21 can also restrain IgE class switch recombination, so both too much and too little IL-21 signaling can be detrimental. Studying GO:0032705 therefore helps researchers identify checkpoints that keep IL-21 within a protective range and provides candidate targets for therapeutic modulation of autoimmune and inflammatory diseases.
• IL-21 is a common gamma-chain cytokine with broad effects on Tfh cells, B cells, and myeloid cells, so its negative regulation shapes multiple immune programs.
• NR2F6 acts as an orphan nuclear receptor that suppresses Tfh cell accumulation by regulating IL-21, directly linking a defined transcription factor to GO:0032705.
• IL-21 is a broad negative regulator of IgE class switch recombination in mouse and human B cells, showing that IL-21 levels must be tightly controlled to avoid allergic dysregulation.
• Unregulated Toll-like receptor 7 signaling in systemic lupus erythematosus drives distinct effector B cell states that contribute to pathogenic responses, a setting where IL-21 regulation is clinically relevant.
• IL-21 has been implicated in chronic inflammatory diseases, making negative regulation of its production a potential anti-inflammatory checkpoint.
• In chronic HBV infection, IL-21 attenuates liver inflammation by enhancing myeloid-derived suppressor cell immunosuppressive function, illustrating context-dependent beneficial roles of IL-21.
• Common gamma-chain cytokines, including IL-21, participate in lung interleukin-22 regulation after acute Aspergillus fumigatus exposure, connecting this GO term to mucosal immune tuning.
• Aging alters B cell trafficking and granzyme B production in double negative B cells, a context in which IL-21-related signals may influence effector B cell behavior.
• CRISPR-based knockout and knock-in models enable causal testing of candidate negative regulators of IL-21 production in primary T cells and cell lines.
• Understanding GO:0032705 supports rational design of therapies that either amplify or restrain IL-21 depending on the disease context.
What Happens During negative regulation of interleukin-21 production?
Transcriptional repression of IL-21
In simple terms: The cell makes less IL-21 because transcription factors or nuclear receptors turn down the IL-21 gene.
Negative regulation of IL-21 production can occur at the transcriptional level when repressive nuclear receptors or transcription factors limit IL21 gene expression in activated T cells. The orphan nuclear receptor NR2F6 suppresses T follicular helper cell accumulation through regulation of IL-21, providing a defined example of a transcriptional brake on IL-21 production. Because IL-21 is a common gamma-chain cytokine with broad immune effects, transcriptional restraint helps prevent excessive Tfh and B cell activation.
Suppression of T follicular helper cell differentiation
In simple terms: If fewer cells become Tfh cells, less IL-21 is produced overall.
IL-21 is produced predominantly by activated CD4+ T cells, including T follicular helper cells, so processes that suppress Tfh cell accumulation indirectly reduce IL-21 production. NR2F6 limits Tfh cell accumulation, thereby lowering the number of IL-21-producing cells and contributing to negative regulation of interleukin-21 production. This differentiation-level control is a key node in GO:0032705 because it reduces the frequency of IL-21-producing cells rather than only the output per cell.
Post-transcriptional and post-translational restraint
In simple terms: Even if the IL-21 gene is switched on, the cell can still reduce how much mature IL-21 protein is made or released.
Negative regulation of interleukin-21 production can also operate after transcription, for example by limiting mRNA stability or protein secretion, although the specific molecular players vary by cell type. Because IL-21 is a secreted cytokine, any process that reduces the frequency, rate, or extent of its production falls under GO:0032705, including mechanisms that act on the biosynthetic pathway. The QuickGO synonym negative regulation of interleukin-21 biosynthetic process captures this biosynthetic dimension of the term.
Feedback control by IL-21 signaling
In simple terms: IL-21 signaling itself can trigger feedback that limits further IL-21 production.
IL-21 signals through its receptor and can influence the differentiation and function of T and B cell subsets, creating feedback loops that shape subsequent cytokine output. In B cells, IL-21 acts as a broad negative regulator of IgE class switch recombination, showing that IL-21 signaling can restrain specific effector programs even as it promotes others. Such context-dependent feedback contributes to the overall negative regulation of interleukin-21 production within an immune response.
Environmental and infection-associated modulation
In simple terms: Signals from infections and the tissue environment can change how much IL-21 is produced.
Common gamma-chain cytokines, including IL-21, participate in lung interleukin-22 regulation after acute exposure to Aspergillus fumigatus, indicating that environmental exposure can modulate related cytokine networks. In chronic HBV infection, IL-21 attenuates liver inflammation by enhancing myeloid-derived suppressor cell immunosuppressive function, illustrating that IL-21 levels and their regulation are context-dependent. These settings show that negative regulation of interleukin-21 production is not a fixed set point but responds to infection and tissue cues.
Key Genes Involved in GO:0032705 negative regulation of interleukin-21 production
The following genes and proteins have been experimentally linked to IL-21 biology, Tfh cell regulation, or immune contexts in which negative regulation of interleukin-21 production is relevant.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL21 | Encodes the interleukin-21 cytokine whose production is negatively regulated in GO:0032705 | Core target gene for measuring IL-21 mRNA and protein output |
| IL21R | Encodes the IL-21 receptor that mediates IL-21 signaling | Defines the signaling axis that can feed back on IL-21 production |
| NR2F6 | Orphan nuclear receptor that suppresses Tfh cell accumulation through regulation of IL-21 | Direct negative regulator linked to reduced IL-21 production |
| BCL6 | Transcriptional regulator of T follicular helper cell differentiation | Tfh differentiation controls the number of IL-21-producing cells |
| MAF | Transcription factor associated with Tfh and IL-21 expression programs | Candidate node for transcriptional control of IL-21 production |
| STAT3 | Signal transducer downstream of IL-21 receptor and other common gamma-chain cytokines | Links IL-21 signaling to transcriptional feedback |
| STAT1 | Signal transducer involved in cytokine responses that can modulate T cell differentiation | Context-dependent regulator of cytokine-producing T cell states |
| PRDM1 | Transcriptional repressor with roles in B cell and T cell differentiation | Candidate repressor of IL-21-associated effector programs |
| IRF4 | Transcription factor required for Tfh and effector T cell programs | Influences the cellular context in which IL-21 is produced |
| TOX | Transcription factor linked to T cell exhaustion and Tfh-like states | Modulates the differentiation state of IL-21-producing cells |
| FOXP3 | Regulatory T cell transcription factor that can restrain effector T cell cytokine production | Indirect negative regulator of IL-21-producing effector T cells |
| IL2 | Common gamma-chain cytokine that shapes T cell differentiation | Competes with or modulates IL-21-producing T cell programs |
| IL6 | Inflammatory cytokine that influences Tfh and Th17 differentiation | Upstream signal that can alter IL-21 production |
| IL10 | Anti-inflammatory cytokine that restrains effector T cell responses | Indirect modulator of IL-21-producing cell activity |
| TLR7 | Toll-like receptor 7, whose unregulated signaling drives pathogenic effector B cells in SLE | Links innate sensing to IL-21-associated pathogenic B cell states |
| CD4 | Marker of helper T cells that are the main IL-21 producers | Defines the primary cell population for studying GO:0032705 |
| CD27 | Marker used to define B cell subsets including double negative B cells | Helps characterize effector B cell populations influenced by IL-21 |
| GZMB | Granzyme B, produced by effector B cells in aging | Readout of effector B cell states in IL-21-related contexts |
How Is negative regulation of interleukin-21 production Regulated?
Negative regulation of interleukin-21 production is itself regulated at multiple levels. The orphan nuclear receptor NR2F6 suppresses T follicular helper cell accumulation through regulation of IL-21, providing a direct transcriptional mechanism that limits IL-21 output. Because IL-21 is a common gamma-chain cytokine, its production is embedded in the broader cytokine network that includes IL-2, IL-6, and other differentiation signals that shape Tfh and effector T cell programs. In B cells, IL-21 acts as a broad negative regulator of IgE class switch recombination, showing that IL-21 signaling can feed back on effector programs in a context-dependent manner. Environmental exposures such as Aspergillus fumigatus can also modulate common gamma-chain cytokine networks, including IL-21-related pathways, in the lung. In chronic HBV infection, IL-21 attenuates liver inflammation by enhancing myeloid-derived suppressor cell function, illustrating that the consequences of IL-21 production are shaped by the tissue environment.
negative regulation of interleukin-21 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL21 | Systemic lupus erythematosus and chronic inflammatory diseases | IL21 knockout or reporter knock-in T cell lines and primary T cells |
| NR2F6 | T follicular helper cell accumulation and autoimmunity | NR2F6 knockout and point-mutation models in CD4+ T cells |
| IL21R | IL-21 signaling in B cell and T cell responses | IL21R knockout B cell lines and primary B cells |
| TLR7 | Pathogenic effector B cells in SLE | TLR7 overexpression and knockout B cell models |
| GZMB | Effector B cell biology in aging | GZMB reporter and knockout B cell models |
Systemic lupus erythematosus and pathogenic effector B cells
Unregulated Toll-like receptor 7 signaling induces distinct effector B cells that contribute to pathogenic responses in systemic lupus erythematosus. Because IL-21 is a key cytokine shaping B cell differentiation and effector function, loss of negative regulation of interleukin-21 production can contribute to the expansion of pathogenic B cell states in SLE. This makes GO:0032705 a relevant process for understanding how checkpoints on IL-21 production protect against autoantibody-driven disease.
Chronic inflammatory diseases
IL-21 has been implicated in chronic inflammatory diseases, where sustained cytokine production can perpetuate tissue inflammation. Negative regulation of interleukin-21 production represents a counterbalancing process that limits the duration and intensity of IL-21-driven inflammation. Studying the genes and pathways that enforce GO:0032705 may reveal targets for reducing chronic inflammatory pathology.
Chronic HBV infection and liver inflammation
In chronic HBV infection, IL-21 attenuates liver inflammation by enhancing myeloid-derived suppressor cell immunosuppressive function. This context shows that IL-21 is not uniformly pathogenic and that its regulation must be understood in a disease-specific manner. Negative regulation of interleukin-21 production could therefore either worsen or improve inflammation depending on the infection setting, underscoring the need for careful experimental models.
IgE-mediated allergy and B cell class switching
IL-21 is a broad negative regulator of IgE class switch recombination in mouse and human B cells. This means that reduced IL-21 production, or loss of its downstream signaling, can de-repress IgE switching and potentially exacerbate allergic responses. GO:0032705 is therefore relevant to allergy research because the negative regulation of IL-21 production indirectly influences IgE class switching.
From negative regulation of interleukin-21 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene reduce IL-21 production? | CRISPR knockout of the candidate gene in CD4+ T cells or Jurkat-derived lines |
| Does a specific point mutation in a transcription factor alter IL-21 repression? | CRISPR point-mutation knock-in of the DNA-binding or dimerization domain |
| Does a candidate repressor bind the IL21 locus in vivo? | Tagged knock-in of the candidate gene with a chromatin or epitope tag |
| Does overexpression of a repressor lower IL-21 output? | CRISPR-mediated overexpression or lentiviral overexpression in primary T cells |
| Does IL-21 feedback control IgE class switching? | IL21 or IL21R knockout in mouse and human B cell cultures |
| Does TLR7 dysregulation alter IL-21-associated B cell states? | TLR7 overexpression or knockout in B cell models |
How to Study the negative regulation of interleukin-21 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RT-qPCR | IL21 mRNA levels | Quantifying transcriptional output after CRISPR perturbation |
| ELISA | Secreted IL-21 protein | Measuring cytokine production in T cell cultures |
| Intracellular cytokine staining | IL-21 protein at single-cell level | Identifying which T cell subsets produce IL-21 |
| ChIP-seq / ChIP-qPCR | Binding of repressors at the IL21 locus | Testing NR2F6 or other candidate repressors |
| ATAC-seq | Chromatin accessibility at IL21 regulatory regions | Assessing whether repression involves chromatin changes |
| CRISPR knockout | Loss-of-function effect on IL-21 production | Identifying negative regulators of IL-21 |
| CRISPR point-mutation knock-in | Effect of specific amino acid changes on repressor function | Dissecting DNA-binding versus protein interaction domains |
| Flow cytometry | Immune cell subset frequencies and effector markers | Linking IL-21 regulation to Tfh and B cell states |
Measuring IL-21 production
Quantifying IL-21 mRNA by RT-qPCR and IL-21 protein by ELISA or intracellular cytokine staining is the primary way to assess negative regulation of interleukin-21 production. Because IL-21 is a secreted cytokine, supernatant ELISA after T cell activation provides a direct readout of the frequency and extent of production. Flow cytometry with IL-21 intracellular staining allows single-cell resolution of which T cell subsets are producing the cytokine.
Transcriptional and chromatin assays
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) or ChIP-qPCR can test whether candidate repressors such as NR2F6 occupy the IL21 locus. ATAC-seq and histone modification profiling can reveal whether negative regulators of IL-21 production act by closing chromatin or removing activating marks. Reporter assays using the IL21 promoter and enhancer regions can map the cis-elements that mediate repression.
CRISPR perturbation and functional genomics
CRISPR knockout screens and targeted knockouts can identify genes whose loss increases IL-21 production, thereby defining negative regulators in GO:0032705. Point-mutation knock-ins can separate DNA-binding from protein-protein interaction functions of candidate repressors. Pooled CRISPR library screening combined with IL-21 readouts enables unbiased discovery of pathways that restrain IL-21 production.
In vivo and disease models
Mouse models of autoimmunity and infection can test whether loss of negative regulation of IL-21 production worsens disease. Adoptive transfer of CRISPR-edited T cells into recipient mice allows causal testing of candidate genes in a physiological context. Infection models such as chronic HBV or Aspergillus fumigatus exposure can reveal context-dependent effects on IL-21-related cytokine networks.
How CRISPR Can Be Used to Study GO:0032705 negative regulation of interleukin-21 production
Knockout
CRISPR knockout of candidate genes such as NR2F6 can test whether loss of a repressor increases IL-21 production, directly probing negative regulation of interleukin-21 production. Knockout of IL21 or IL21R provides control models for loss of the cytokine or its receptor. Pooled knockout screens in primary T cells or T cell lines can nominate new negative regulators of IL-21 production.
Point Mutation
Point-mutation knock-in can dissect the functional domains of repressors such as NR2F6, for example by mutating DNA-binding residues to test whether direct DNA binding is required for IL-21 repression. Point mutations in IL21R can separate signaling functions that feed back on IL-21 production. These models are essential for distinguishing correlation from causation in GO:0032705.
Knock-in
Tagged knock-in of candidate repressors with epitope or fluorescent tags enables ChIP-seq and imaging at endogenous expression levels. Knock-in of reporter cassettes at the IL21 locus allows real-time monitoring of IL-21 production in living cells. Knock-in of disease-associated variants can test their impact on negative regulation of IL-21 production.
Overexpression
CRISPR-mediated or lentiviral overexpression of candidate repressors can test whether increased dosage reduces IL-21 production. Overexpression of TLR7 in B cell models can mimic the unregulated TLR7 signaling seen in systemic lupus erythematosus and its effects on IL-21-associated B cell states. Overexpression models complement knockout studies by testing sufficiency of a regulator in GO:0032705.
How EDITGENE Supports negative regulation of interleukin-21 production Research
Researchers studying negative regulation of interleukin-21 production-related genes often need to determine whether a candidate gene is causally involved in reducing IL-21 output, and CRISPR-based models provide the most direct way to test this. EDITGENE supports this work with knockout, point-mutation, knock-in, overexpression cell models, and CRISPR library screening combined with bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-21 production research.
Frequently Asked Questions About negative regulation of interleukin-21 production
What is GO:0032705?
GO:0032705 is the Gene Ontology term for negative regulation of interleukin-21 production, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-21 production.
What is negative regulation of interleukin-21 production?
It is any biological process that lowers the amount of IL-21 a cell produces, whether by reducing transcription, altering T cell differentiation, or acting post-transcriptionally.
What genes are involved in negative regulation of interleukin-21 production?
Key genes include NR2F6, which suppresses Tfh cell accumulation through regulation of IL-21, as well as IL21, IL21R, and transcription factors that shape Tfh and effector T cell programs.
Which cytokine is regulated by GO:0032705?
GO:0032705 regulates interleukin-21, a common gamma-chain cytokine produced mainly by activated CD4+ T cells and T follicular helper cells.
How is IL-21 production negatively regulated?
IL-21 production can be negatively regulated by transcriptional repressors such as NR2F6, by suppression of Tfh cell differentiation, and by post-transcriptional or feedback mechanisms.
Why is negative regulation of IL-21 production important in lupus?
Unregulated Toll-like receptor 7 signaling drives pathogenic effector B cells in systemic lupus erythematosus, and loss of IL-21 checkpoints may contribute to these pathogenic B cell states.
Does IL-21 regulate IgE class switching?
Yes, IL-21 acts as a broad negative regulator of IgE class switch recombination in mouse and human B cells.
What diseases are linked to IL-21 dysregulation?
IL-21 has been linked to systemic lupus erythematosus, chronic inflammatory diseases, chronic HBV infection, and IgE-mediated allergy contexts.
How can CRISPR be used to study negative regulation of IL-21 production?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models can test whether candidate genes causally reduce IL-21 production in T cells and B cells.
What methods measure IL-21 production?
RT-qPCR, ELISA, intracellular cytokine staining, ChIP-seq, ATAC-seq, and flow cytometry are commonly used to measure IL-21 production and its regulation.
Conclusion
GO:0032705, negative regulation of interleukin-21 production, captures the checkpoints that keep IL-21 within a physiological range. These checkpoints include transcriptional repression by NR2F6, suppression of Tfh cell differentiation, and context-dependent feedback from IL-21 signaling itself. Because IL-21 influences B cell class switching, autoimmunity, and chronic inflammation, understanding its negative regulation is directly relevant to diseases such as systemic lupus erythematosus and chronic inflammatory conditions. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with cytokine assays and functional genomics, provide a rigorous path to identify and validate the genes that enforce GO:0032705. EDITGENE supports these efforts with tailored cell model generation, library screening, and bioinformatics services.
References
- 1. Jenks SA et al.. 2018. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus.. Immunity 49(4):725-739.e6 PMID: 30314758
- 2. Leonard WJ et al.. 2008. Interleukin 21: a cytokine/cytokine receptor system that has come of age.. J Leukoc Biol 84(2):348-56 PMID: 18467657
- 3. Sarra M et al.. 2013. Interleukin-21 in chronic inflammatory diseases.. Biofactors 39(4):368-73 PMID: 23553807
- 4. Li X et al.. 2025. IL-21 attenuates liver inflammation by enhancing myeloid-derived suppressor cells immunosuppressive function in chronic HBV infection.. J Transl Med 23(1):1410 PMID: 41419948
- 5. Reeder KM et al.. 2018. Role of Common γ-Chain Cytokines in Lung Interleukin-22 Regulation after Acute Exposure to Aspergillus fumigatus.. Infect Immun 86(10) PMID: 30104211
- 6. Yang Z et al.. 2020. IL-21 is a broad negative regulator of IgE class switch recombination in mouse and human B cells.. J Exp Med 217(5) PMID: 32130409
- 7. Olson WJ et al.. 2019. Orphan Nuclear Receptor NR2F6 Suppresses T Follicular Helper Cell Accumulation through Regulation of IL-21.. Cell Rep 28(11):2878-2891.e5 PMID: 31509749
- 8. Bulati M et al.. 2014. Trafficking phenotype and production of granzyme B by double negative B cells (IgG(+)IgD(-)CD27(-)) in the elderly.. Exp Gerontol 54:123-9 PMID: 24389059
